CAS 1643913-93-2

Formule : C35H29F3N4O3

InChI : InChI=1S/C35H29F3N4O3/c36-28-9-7-24(8-10-28)30-19-26(23-3-5-25(6-4-23)34(44)42-15-13-35(37,38)14-16-42)17-27-18-29(45-33(27)30)21-41-32(43)12-2-22-1-11-31(39)40-20-22/h1-12,17-20H,13-16,21H2,(H2,39,40)(H,41,43)/b12-2+

Code InChI : MRFOPLWJZULAQD-SWGQDTFXSA-N

SMILES : C1CN(CCC1(F)F)C(=O)C2=CC=C(C=C2)C3=CC(=C4C(=C3)C=C(O4)CNC(=O)/C=C/C5=CN=C(C=C5)N)C6=CC=C(C=C6)F

2-​Propenamide, 3-​(6-​amino-​3-​pyridinyl)​-​N-​[[5-​[4-​[(4,​4-​difluoro-​1-​piperidinyl)​carbonyl]​phenyl]​-​7-​(4-​fluorophenyl)​-​2-​benzofuranyl]​methyl]​-​, (2E)​-

CAS : 1643913-93-2

Formule : C₃₅H₂₉F₃N₄O₃

Degré de pureté : 98%

Couleur et forme : Solid

Masse moléculaire : 610.6250

Ref: IN-DA001UUS

KPT9274

CAS : 1643913-93-2

KPT9274

Formule : C₃₅H₂₉F₃N₄O₃

Degré de pureté : ≥98%

Masse moléculaire : 610.62

Ref: 54-BUP05419

Padnarsertib

CAS : 1643913-93-2

(E)-3-(6-aminopyridin-3-yl)-N-((5-(4-(4,4-difluoropiperidine-1-carbonyl)phenyl)-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide

Formule : C₃₅H₂₉F₃N₄O₃

Degré de pureté : 98%

Masse moléculaire : 610.63

Ref: IN-DG630415

KPT 9274 (ATG-019)

CAS : 1643913-93-2

Formule : C₃₅H₂₉F₃N₄O₃

Masse moléculaire : 610.64

Ref: 4Z-K-031074

KPT9274

CAS : 1643913-93-2

KPT9274 (PAK4-IN-1) is a non-competitive dual inhibitor of PAK4 and NAMPT(IC50= ~120 nM). It is an orally bioavailable small molecule.

Formule : C₃₅H₂₉F₃N₄O₃

Degré de pureté : 99.01% - 99.93%

Couleur et forme : Solid

Masse moléculaire : 610.625

Ref: TM-T4354

KPT9274

CAS : 1643913-93-2

Formule : C₃₅H₂₉F₃N₄O₃

Masse moléculaire : 610.6

Ref: BE-RMCK020072

KPT 9274

CAS : 1643913-93-2

KPT 9274 is a molecule that binds to the citric acid cycle effector protein, β-catenin. It has minimal toxicity and is energy-independent. KPT 9274 blocks ATP production by binding to the death protein and inhibits atp production. KPT 9274 has been shown to be effective against high-risk disease such as acute myeloid leukemia (AML). The pharmacokinetic properties of KPT 9274 have been studied in vivo using a rat model. This drug is metabolized by fatty acid oxidation and glucuronidation in the liver and excreted in bile.

Formule : C₃₅H₂₉F₃N₄O₃

Degré de pureté : Min. 95%

Masse moléculaire : 610.63 g/mol

Ref: 3D-FA103866